Dr. Hompesch to Present at India’s International Conference on Clinical Pharmacology-Translational Research and China’s DIA Annual Meeting, and Dr. Morrow to Present at the Annual Meeting of Japan Diabetes Society
SAN DIEGO, April 15, 2014 – Profil® Institute for Clinical Research, Inc., an early phase clinical research organization focused on diabetes and obesity, announced today invited presentations by CEO Dr. Marcus Hompesch at the International Conference on Clinical Pharmacology-Translational Research in Mumbai, India and the DIA China Annual Meeting in Shanghai, and a poster presentation by COO Dr. Linda Morrow at the Annual Meeting of Japan Diabetes Society in Osaka, Japan.
The 7th International Conference on Clinical Pharmacology-Translational Research will take place April 17-20 in Mumbai. The conference is hosted by the South Asian Chapter of American College of Clinical Pharmacology with tracks focused on translational research for diabetes, oncology, as well as cardiovascular and infectious disease. Profil Institute’s Dr. Hompesch is an invited speaker and will present April 20 on the topic “Translational Research in Early Phase Clinical Development of Diabetes Drugs: What does it mean and how can it be done?”
The 6th DIA China Annual Meeting will take place May 11-14 in Shanghai. The DIA China Annual Meeting is the largest annual conference held in the Asia Pacific region and features high-level representatives from the government, biopharma industry and academia in China and abroad. Dr. Hompesch is an invited speaker and will present on the topic “Early Phase Clinical Research and Development for Diabetes and Obesity.”
The 57th Annual Meeting of Japan Diabetes Society will take place May 22-24 in Osaka. The annual meeting features researchers from academia and the biopharma industry and physicians from clinical practice, speaking on topics from drug discovery research to best practices in patient care. Profil Institute’s Dr. Morrow will present a poster titled “Exhibits a Flatter Glucodynamic Profile than Insulin Glargine (GL) at Steady State in Subjects with Type 1 Diabetes.”
More information about conference presentations by Profil Institute scientists is available on the company’s website at http://www.profilinstitute.com/news-events/conferences/.
About Profil Institute for Clinical Research, Inc.
Profil Institute for Clinical Research, Inc. is a science driven, early phase clinical research organization focused on diabetes and obesity. The company is renowned as a center of excellence for metabolic clinical research and development based on its scientific expertise, depth of services, and research methodologies. Operational since 2004, Profil Institute is a trusted partner and service provider for its clients from small virtual companies to large pharma and drug discovery companies, as well as academic centers, throughout the Americas, Europe and Asia.
Profil Institute works with clients to design and execute first-in-human, proof of mechanism clinical research for metabolic drug and device candidates. To date, Profil Institute has completed more than 200 phase I-IIa diabetes and obesity clinical studies, involving every clinically relevant diabetes drug class and a wide array of medical devices. In addition to clinical research, Profil Institute provides early phase clinical development services and consulting, including the design of strategic clinical development plans and management of regulatory affairs. For more information visit www.profilinstitute.com.
For further information, please contact: